West Virginia Medicaid Drug Utilization Review Board Minutes

September 26, 2018

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Lester Labus, MD, Chair
K.C. Lovin, PA-C, Vice Chair
Michael Lonsinger, PharmD
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS
Chris Terpening, PharmD, PhD
Michael Ballow, PharmD (via phone)
Christopher Booth, PharmD (via phone)
Scott Brown, RPh

Members Absent:

C.K. Babcock, PharmD
Myra Chiang, MD
Kate Forman, PharmD
John Guilfoose, MD
John Vanin, MD

DHHR/BMS Staff:

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant
Gail Goodnight, RPh, Rebate Pharmacist

Contract Staff:

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Brent Breeding, RPh, Change Healthcare

I. INTRODUCTIONS

A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:06 p.m. EDT. The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM May 23, 2018 DUR BOARD MEETING

A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

III. OLD BUSINESS

1. **None**

IV. NEW BUSINESS

A. Speakers

1.	Dr. David Watson	WVU	Aimovig
2.	Michael Philbin	Teva	Austedo
3.	Dr. Judy Curtis	Sunovion	Latuda
4.	Diane Darling	Neurocrine	Ingrezza

B. Updates from the August 22, 2018 Pharmacy & Therapeutics Committee Meeting

1. Dr. Labus and the Board reviewed the updates from the August 22, 2018 P&T meeting. No criteria changes were requested beyond those presented in section III-C of this document.

C. PDL Prior Authorization Criteria (Attachment A)

1. **Dificid –** The Board was notified of a change in the PA Critieria for Dificid, removing the requirement for metronidazole as per clinical guidelines for treatment of C. difficile infections.
2. **Antipsychotics, Atypical**– A motion to approve the criteria as presented was made, seconded, and passed.
3. **Hypoglycemics, GLP-1 Agonists and SGLT2 Inhibitors –** A motion to approve the criteria as presented was made, seconded, and passed.
4. **Toujeo Solostar and Toujeo Max Solostar –** A motion to approve the criteria as presented was made, seconded, and passed.
5. **Irritable Bowel Agents/Short Bowel Syndrome –** A motion was made, seconded and passed to create an electronic edit preventing the use of Trulance and Linzess concurrently with opioids.
6. **Rhopressa –** A motion to approve the criteria as presented was made, seconded, and passed.
7. **Sublocade –** A motion to approve the criteria as presented was made, seconded, and passed.
8. **Sedative Hypnotics -** A motion to approve the criteria as presented was made, seconded, and passed, with one change, requiring 30-day trials of "all" preferred agents, instead of "the" preferred agents for entire class.
9. **Stimulants and Related Agents –** A motion to change the presented criteria was made, seconded, and passed as follows:
   - **a.** Change in class criteria to add "PLEASE NOTE: Requests for amphetamine or methylphenidate IR + ER combination therapy must be for the same active ingredient in the same salt form, if available."
   - **b.** Change in class criteria to add "and mechanism of action" to non-preferred criteria agents: …require 30-day trial of at least one preferred agent …with similar duration of effect and mechanism of action..."
   - **c.** Remove from Non-Amphetamine sub class, the Kapvay/clonidine ER specific criteria.

10. **Aimovig –** A motion to approve the criteria as presented was made, seconded, and passed with the following changes:
    a. Change the PA Criteria from "Patient has failed a 4-month trial of…" to "Patient has failed a 3-month trial of…":
    b. For continuation: Additional therapy may be approved only with clinical documentation showing a 50% reduction in either the number of headache days per month or the overall symptom severity (as measured by MIDAS or HIT-6) compared to baseline.
11. **Austedo / Ingrezza –** A motion to approve the criteria as presented was made, seconded, and passed.
12. **Orlissa –** A motion to approve the criteria as presented was made, seconded, and passed.
13. **Xolair –** A motion to approve the criteria as presented was made, seconded, and passed.

V. REPORTS

A. Molina Quarterly Report – Eric Sears presented an overview of the Molina 2018 Second Quarter Report (Attachment B). The presentation included a review of the DUR Quarterly Overall Summary Report.

B. Rational Drug Therapy Program – Steve Small presented information on changes at RDTP during the Second and Third Quarter 2018.

VI. OTHER BUSINESS – OPEN TO THE FLOOR

A. None

VII. NEXT MEETING AND ADJOURNMENT

A. A motion to adjourn the meeting was made, seconded, and passed.

B. The meeting concluded at 6:14 p.m. EDT.

C. The next meeting will be Wednesday, November 14, 2018 from 4:00p.m.–6:00p.m. at WVDHHR.

Submitted by:

Doug Sorvig – BMS, WVDHHR